Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00XWD
|
|||
| Former ID |
DAP001526
|
|||
| Drug Name |
Tegaserod
|
|||
| Synonyms |
Tegaserod (USAN/INN); 1-[[(Z)-(5-methoxyindol-3-ylidene)methyl]amino]-2-pentylguanidine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Irritable bowel syndrome [ICD-11: DD91.0; ICD-10: K55-K64, K58; ICD-9: 564.1, 787.91] | Approved | [1] | |
| Dyspepsia [ICD-11: MD92] | Withdrawn from market | [2], [3] | ||
| Gastro-oesophageal reflux [ICD-11: DA22] | Withdrawn from market | [2], [3] | ||
| Company |
Novartis
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H23N5O
|
|||
| Canonical SMILES |
CCCCCN=C(N)NN=CC1=CNC2=C1C=C(C=C2)OC
|
|||
| InChI |
1S/C16H23N5O/c1-3-4-5-8-18-16(17)21-20-11-12-10-19-15-7-6-13(22-2)9-14(12)15/h6-7,9-11,19H,3-5,8H2,1-2H3,(H3,17,18,21)/b20-11+
|
|||
| InChIKey |
IKBKZGMPCYNSLU-RGVLZGJSSA-N
|
|||
| CAS Number |
CAS 145158-71-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
11364906, 11367468, 11370030, 11372869, 11374139, 11378200, 11484916, 11488916, 11491670, 11492545, 11495764, 14776170, 14776171, 26612950, 26749090, 26749091, 34746101, 39384500, 46523984, 47207714, 47662545, 47960011, 48110734, 50107521, 50107522, 53788768, 56464350, 57362102, 78780358, 92124752, 92712636, 93301629, 103276928, 104098381, 114150049, 116933602, 126625387, 126656585, 126667358, 134338707, 134358317, 135018998, 135087697, 135374357, 135651238, 137090514, 137175472, 138069543, 138069544, 138069548
|
|||
| ChEBI ID |
CHEBI:51043
|
|||
| ADReCS Drug ID | BADD_D02139 ; BADD_D02140 | |||
| SuperDrug ATC ID |
A06AX06
|
|||
| SuperDrug CAS ID |
cas=145158710
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 4 receptor (HTR4) | Target Info | Agonist | [3] |
| KEGG Pathway | Calcium signaling pathway | |||
| cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Serotonergic synapse | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| 5HT4 type receptor mediated signaling pathway | ||||
| Pathwhiz Pathway | Excitatory Neural Signalling Through 5-HTR 4 and Serotonin | |||
| Reactome | Serotonin receptors | |||
| G alpha (s) signalling events | ||||
| WikiPathways | Serotonin Receptor 4/6/7 and NR3C Signaling | |||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 226). | |||
| REF 3 | Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.